ClinicalTrials.Veeva

Menu
S

Sarkis Clinical Trials | Gainesville, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SPD489
Lisdexamfetamine Dimesylate
SPD503
Rapastinel
PRC-063
Balovaptan
Aripiprazole
Lisdexamfetamine dimesylate
BI 1358894
Modafinil

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 100 total trials

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-2)

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Other: Placebo
Drug: Aticaprant

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Enrolling
Depressive Disorder, Major
Drug: Aticaprant

This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is t...

Enrolling
Depressive Disorder, Major
Drug: Placebo matching BI 1569912
Drug: BI 1569912

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: ENX-102

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling
Attention-Deficit/Hyperactivity Disorder
Drug: Placebo
Drug: 100mg SPN-812

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18...

Enrolling
Acute Treatment of Migraine
Drug: Rimegepant (PF-07899801)

Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients

Active, not recruiting
Attention-Deficit/Hyperactivity Disorder
Drug: SPN-812

The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizop...

Active, not recruiting
Bipolar I Disorder
Schizophrenia
Drug: Cariprazine Flexible Dose

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling
Pediatric Migraine
Drug: Rimegepant/BHV3000
Drug: Matching placebo

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Placebo-Matching Ubrogepant
Drug: Ubrogepant

Trial sponsors

Shire logo
Pfizer logo
Sumitomo Pharma logo
AbbVie logo
Janssen (J&J Innovative Medicine) logo
Allergan logo
Otsuka logo
Supernus Pharmaceuticals logo
Allergan logo
Boehringer Ingelheim logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems